Investors from all over the world are buying Dr. Reddy’s share- Dr. Reddy’s share in a week 21 percent, 18 percent in 1 month, 91 percent in six months, 95 percent in a year have been given bumper returns.
Also read- The news required for SBI 40 crore customers! Bank changed 4 rules
Now what to do investors- The world’s largest rating agency Credit Suisse has given outperform rating on doctors Reddys and has increased the target from Rs 5100 to Rs 5750. Cash flow is possible up to $ 70 million from Revlimid generic. It is one of the 2 companies selling Avigan in the US. The company can increase its market share in Suboxone.
At the same time, the US Bank City has stated in its report that after March 2022, it can launch Revlimid in the US. This will be the third settlement for Revlimid after NATCO, Alvogen.
There is a big deal with Corona vaccine – The Russian Direct Investment Fund (RDIF) will work closely with Dr. Reddy’s Laboratories for testing and distribution of its vaccine Sputnik-5 against Kovid-19 in India.
RDIF Chief Executive Officer Kiril Damitrev gave this information on Wednesday. He said that RDIF is interacting with Indian regulators to ensure that all necessary conditions are met for clinical testing of vaccines.
Damitriyev said in an interview to ‘PTI-language’ on an e-mail, “RDIF and Global Drug Company Dr. Reddy Laboratories Limited, headquartered in India, have agreed to supply 10 million Russian Sputnic-5 vaccines and they will also work together on the clinical testing and distribution of vaccines in India.
The vaccine against the corona virus has been created by the Gamalaya National Rogics and Microorganism Research Institute and RDIF. Damitriyev said that the additional clinical study of Sputnik-5 will be done in other countries including Brazil, India, Saudi Arabia, Egypt, United Arab Emirates and Belarus. Russia said earlier this month that it is in touch with Indian officials on the issue of vaccine.